![Breast cancer study abstract on PubMed](/sites/default/files/styles/landscape_480x260/public/media/2023-02/breast-cancer-study-abstract-on-pubmed.png?h=6f91572f&itok=4r4hy2KD)
March 2022
Contact: Lydia Pace
Email: Lepace@partners.org
Testing for BRCA1/2 pathogenic variants is recommended for women aged ≤45 years with breast cancer. Some studies have found racial/ethnic and socioeconomic disparities in testing. We linked Massachusetts' All-Payer Claims Database with Massachusetts Cancer Registry data to assess factors associated with BRCA1/2 testing among young women with breast cancer in Massachusetts, a state with high levels of access to care and equitable insurance coverage of breast cancer gene (BRCA) testing.
Related Links
Carriers
Categories
Purpose